MetaCap

Alumis (ALMS) vs Climb Bio (CLYM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Climb Bio (CLYM) has outperformed Alumis (ALMS) over the past year, gaining 440.6% versus a loss of 45.8%. Climb Bio is the larger company by market cap ($539.8 million vs $514.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALMS-45.75%CLYM+440.59%
+999%+452%-96%
Nov 21, 20251 yearNov 20, 2026
ALMS-70.23%CLYM+29.25%
+154%+30%-95%
Jun 24, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALMS versus CLYM key metrics
MetricALMSCLYM
Share price$3.96$9.19
Market cap$514.09M$539.80M
1-day change-8.55%-0.97%
YTD return-59.43%+129.75%
1-year return-45.75%+440.59%
5-year return—-33.21%
EPS (TTM)$-3.53$-0.81
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$24.05M—
Net income (latest FY)$-243.32M$-59.85M
Operating margin-1886.92%—
Net margin-1011.75%—
52-week high$31.35$18.33
52-week low$3.94$1.64
Distance from 52-week high-87.37%-49.86%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+540.91%+209.03%
Average volume2.87M1.38M
Shares outstanding129.82M58.74M
Employees25128
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CLYM has outperformed ALMS by 486.3 percentage points over the past year.

About Alumis

ALMS stock →

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 251 employees

About Climb Bio

CLYM stock →

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

ALMS vs CLYM FAQ

Which is bigger, Alumis or Climb Bio?

Climb Bio (CLYM) is larger, with a market capitalization of $539.80M compared with $514.09M for Alumis (ALMS).

Which stock has performed better over the past year, ALMS or CLYM?

CLYM returned +440.59% over the past 12 months, compared with -45.75% for ALMS (price return, excluding dividends). Past performance does not predict future results.

Are Alumis and Climb Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons